<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00848497</url>
  </required_header>
  <id_info>
    <org_study_id>H-21148</org_study_id>
    <nct_id>NCT00848497</nct_id>
  </id_info>
  <brief_title>Testosterone for Penile Rehabilitation After Radical Prostatectomy</brief_title>
  <official_title>Efficacy of Testosterone Replacement Therapy in Penile Rehabilitation Following Radical Prostatectomy (#: 04-07-30-01)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mohit Khera</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness of testosterone replacement
      therapy (TRT) in men following surgery to remove the prostate in improving erectile function.
      Subjects will be randomized (like flipping a coin) to one of two groups. One group will
      receive Testim® (testosterone gel) 5 g per day plus Viagra 25 mg every night and the other
      will receive Placebo-Testim® 5 g per day plus Viagra 25 mg every night.

      Subjects will begin drug treatment 3 months after the initial screening visit and will take
      study drug for 3 months only. Participation will end at the end of the 6-month visit.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There was only one patient who began treatment with the study drug. After blind was broken,
      it was noted that he received placebo Testim and Viagra.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of volunteers who would consent to participate and lack of funding
  </why_stopped>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in SHIM (Sexual Health Inventory for Males) Score at 6 Months After Initial Screening Visit.</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>SHIM range is 0-25. 0= no sexual activity;1-7 severe ED; 8-11 Moderate ED; 12-16 Mild to Moderate ED; 17-21 Mild ED</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the IIEF (International Index of Erectile Function) Score 6 Months After the Initial Screening Visit.</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>There are 15 questions, each divided into 5 domains. Maximum score is 75 = best function, and minimum is 5 = worst function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the ADAM (Androgen Deficiency in the Aging Male)Score 6 Months After the Initial Screening Visit.</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>ADAM scores of one evaluated patient. ADAM is 10 questions (&quot;yes&quot; or &quot;no&quot; answers) and if you answer yes to question 1 or 7 or &quot;yes&quot; to any 3 questions you are said to test &quot;positive&quot; to the ADAM questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the EPIC (Expanded Prostate Cancer Index Composite) Score 6 Months After the Initial Screening Visit.</measure>
    <time_frame>Basline and 6 months</time_frame>
    <description>EPIC is scored from 0 -100,lower EPIC score= worse, higher EPIC score= better</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Hypogonadism</condition>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Testim® + Viagra®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Testim® gel (50 mg of testosterone) once daily + Viagra® 25 mg tablet every night</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Testim® + Viagra®</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Testim® gel once daily + Viagra® 25 mg tablet every night</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testim®</intervention_name>
    <description>Testim® 5 g of gel (one tube) containing 50 mg of testosterone once daily. This was the dose given to the patient which he started.</description>
    <arm_group_label>Testim® + Viagra®</arm_group_label>
    <other_name>Testim® is the brand name for testosterone gel.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Testim®</intervention_name>
    <description>Placebo Testim® 5 g of gel (one tube)</description>
    <arm_group_label>Placebo Testim® + Viagra®</arm_group_label>
    <other_name>Placebo Testim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Viagra®</intervention_name>
    <description>Viagra 25mg was the dose given to the patient which he started.</description>
    <arm_group_label>Testim® + Viagra®</arm_group_label>
    <arm_group_label>Placebo Testim® + Viagra®</arm_group_label>
    <other_name>Viagra® is the brand name for sildenafil citrate.</other_name>
    <other_name>Viagra® 25 mg tablet daily at night</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males, 18 years of age or older, with low testosterone levels.

          -  Must have undergone a bilateral nerve sparing radical prostatectomy.

          -  Nadir PSA (Prostate-Specific Antigen) values should be less than 0.01 ng/ml on two
             consecutive occasions separated by 4 weeks at the start of treatment.

          -  Must give informed consent.

          -  Must be willing to complete follow-up visits.

        Exclusion Criteria:

          -  Testosterone level greater than 300 ng/ dl

          -  Hemoglobin level greater than 18 ng/dl.

          -  Positive surgical margins or evidence of residual prostate cancer after surgery.

          -  Clinically suspected advanced disease or actual evidence of metastatic prostate
             cancer.

          -  Primary Gleason Grade greater than 3 or secondary Gleason Grade greater than 4 in the
             final pathologic specimen will be excluded.

          -  Taking nitrates or with contraindications to the use of Viagra or androgen therapy
             will be excluded.

          -  Known hypersensitivity to any component of the tablet will be excluded.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohit Khera, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Khera M, Grober ED, Najari B, Colen JS, Mohamed O, Lamb DJ, Lipshultz LI. Testosterone replacement therapy following radical prostatectomy. J Sex Med. 2009 Apr;6(4):1165-1170. doi: 10.1111/j.1743-6109.2009.01161.x. Epub 2009 Jan 22.</citation>
    <PMID>19207277</PMID>
  </reference>
  <reference>
    <citation>Khera M, Lipshultz LI. The role of testosterone replacement therapy following radical prostatectomy. Urol Clin North Am. 2007 Nov;34(4):549-53, vi. Review.</citation>
    <PMID>17983894</PMID>
  </reference>
  <reference>
    <citation>Khera M. Androgens and erectile function: a case for early androgen use in postprostatectomy hypogonadal men. J Sex Med. 2009 Mar;6 Suppl 3:234-8. doi: 10.1111/j.1743-6109.2008.01159.x. Epub 2009 Jan 21. Review.</citation>
    <PMID>19207279</PMID>
  </reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2009</study_first_submitted>
  <study_first_submitted_qc>February 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2009</study_first_posted>
  <results_first_submitted>March 18, 2013</results_first_submitted>
  <results_first_submitted_qc>June 2, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 19, 2015</results_first_posted>
  <last_update_submitted>June 2, 2015</last_update_submitted>
  <last_update_submitted_qc>June 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Mohit Khera</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>hormone replacement therapy</keyword>
  <keyword>radical prostatectomy</keyword>
  <keyword>erectile dysfunctions</keyword>
  <keyword>scheduled for removal of prostate gland</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was approved for enrollment on 11/28/2007 and was closed on 1/25/13. Participants were consented in the Baylor Urology clinic setting.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Testim + Viagra</title>
          <description>Testim® gel (50 mg of testosterone)once daily + Viagra® 25 mg tablet every night</description>
        </group>
        <group group_id="P2">
          <title>Placebo Testim + Viagra</title>
          <description>Placebo Testim® gel (50 mg of testosterone) once daily + Viagra® 25 mg tablet every night</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1">Completed Visit 4</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screen failure</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Arm 1 = 2 Arm 2 = 1</population>
      <group_list>
        <group group_id="B1">
          <title>Arm 1</title>
          <description>Testim® gel (50 mg of testosterone)once daily + Viagra® 25 mg tablet every night</description>
        </group>
        <group group_id="B2">
          <title>Arm 2</title>
          <description>Placebo Testim® gel (50 mg of testosterone) once daily + Viagra® 25 mg tablet every night</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" spread="4"/>
                    <measurement group_id="B2" value="59" spread="0"/>
                    <measurement group_id="B3" value="56" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in SHIM (Sexual Health Inventory for Males) Score at 6 Months After Initial Screening Visit.</title>
        <description>SHIM range is 0-25. 0= no sexual activity;1-7 severe ED; 8-11 Moderate ED; 12-16 Mild to Moderate ED; 17-21 Mild ED</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>Baseline = 0 5 months = 0</population>
        <group_list>
          <group group_id="O1">
            <title>Testim + Viagra</title>
            <description>Testim® gel (50 mg of testosterone)once daily + Viagra® 25 mg tablet every night
SHIM at Baseline = N/A SHIM at 5 months = N/A</description>
          </group>
          <group group_id="O2">
            <title>Placebo Testim + Viagra</title>
            <description>Placebo Testim® gel (50 mg of testosterone) once daily + Viagra® 25 mg tablet every night
SHIM at Baseline = 0 SHIM at 5 months = 0</description>
          </group>
        </group_list>
        <measure>
          <title>Change in SHIM (Sexual Health Inventory for Males) Score at 6 Months After Initial Screening Visit.</title>
          <description>SHIM range is 0-25. 0= no sexual activity;1-7 severe ED; 8-11 Moderate ED; 12-16 Mild to Moderate ED; 17-21 Mild ED</description>
          <population>Baseline = 0 5 months = 0</population>
          <units>units on a scale</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the IIEF (International Index of Erectile Function) Score 6 Months After the Initial Screening Visit.</title>
        <description>There are 15 questions, each divided into 5 domains. Maximum score is 75 = best function, and minimum is 5 = worst function</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>Baseline = 5 5 months = 6</population>
        <group_list>
          <group group_id="O1">
            <title>Testim + Viagra</title>
            <description>Testim® gel (50 mg of testosterone)once daily + Viagra® 25 mg tablet every night</description>
          </group>
          <group group_id="O2">
            <title>Placebo Testim + Viagra</title>
            <description>Placebo Testim® gel (50 mg of testosterone) once daily + Viagra® 25 mg tablet every night</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the IIEF (International Index of Erectile Function) Score 6 Months After the Initial Screening Visit.</title>
          <description>There are 15 questions, each divided into 5 domains. Maximum score is 75 = best function, and minimum is 5 = worst function</description>
          <population>Baseline = 5 5 months = 6</population>
          <units>units on a scale</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the ADAM (Androgen Deficiency in the Aging Male)Score 6 Months After the Initial Screening Visit.</title>
        <description>ADAM scores of one evaluated patient. ADAM is 10 questions (“yes” or “no” answers) and if you answer yes to question 1 or 7 or “yes” to any 3 questions you are said to test “positive” to the ADAM questionnaire.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>Baseline = Positive 5 months = Positive</population>
        <group_list>
          <group group_id="O1">
            <title>Testim + Viagra</title>
            <description>Testim® gel (50 mg of testosterone)once daily + Viagra® 25 mg tablet every night</description>
          </group>
          <group group_id="O2">
            <title>Placebo Testim + Viagra</title>
            <description>Placebo Testim® gel (50 mg of testosterone) once daily + Viagra® 25 mg tablet every night</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the ADAM (Androgen Deficiency in the Aging Male)Score 6 Months After the Initial Screening Visit.</title>
          <description>ADAM scores of one evaluated patient. ADAM is 10 questions (“yes” or “no” answers) and if you answer yes to question 1 or 7 or “yes” to any 3 questions you are said to test “positive” to the ADAM questionnaire.</description>
          <population>Baseline = Positive 5 months = Positive</population>
          <units>number of yes answers</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the EPIC (Expanded Prostate Cancer Index Composite) Score 6 Months After the Initial Screening Visit.</title>
        <description>EPIC is scored from 0 -100,lower EPIC score= worse, higher EPIC score= better</description>
        <time_frame>Basline and 6 months</time_frame>
        <population>Baseline = 98
5 months = 87</population>
        <group_list>
          <group group_id="O1">
            <title>Testim + Viagra</title>
            <description>Testim® gel (50 mg of testosterone)once daily + Viagra® 25 mg tablet every night</description>
          </group>
          <group group_id="O2">
            <title>Placebo Testim + Viagra</title>
            <description>Placebo Testim® gel (50 mg of testosterone) once daily + Viagra® 25 mg tablet every night</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the EPIC (Expanded Prostate Cancer Index Composite) Score 6 Months After the Initial Screening Visit.</title>
          <description>EPIC is scored from 0 -100,lower EPIC score= worse, higher EPIC score= better</description>
          <population>Baseline = 98
5 months = 87</population>
          <units>units on a scale</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm 1</title>
          <description>Testim® gel (50 mg of testosterone)once daily + Viagra® 25 mg tablet every night</description>
        </group>
        <group group_id="E2">
          <title>Arm 2</title>
          <description>Placebo Testim® gel (50 mg of testosterone) once daily + Viagra® 25 mg tablet every night</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The subject that completed the study reported no adverse reactions or events.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Mohit Khera, MD</name_or_title>
      <organization>Baylor College of Medicine</organization>
      <phone>713-798-6593</phone>
      <email>mkhera@bcm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

